Overview

A Study to Assess the Safety, Tolerability and Efficacy of IONIS-AGT-LRx, an Antisense Inhibitor Administered Subcutaneously to Hypertensive Subjects With Controlled Blood Pressure

Status:
Completed

Trial end date:
2019-11-13

Target enrollment:

Participant gender:

Summary

This will be a Phase 2, double-blind, randomized, placebo-controlled study of IONIS-AGT-LRx conducted in mild hypertensive subjects.

Phase:

Phase 2

Details

Lead Sponsor:

Ionis Pharmaceuticals, Inc.